22. November 2023
Document
Publication in 25th Guide to German Biotech Companies
Zedira has been featured in the jubilee edition of the 25th Guide to German Biotech Companies!
Highlighted Profile Features:
Business Unit: Drug Discovery - Design of small molecule transglutaminase inhibitors
Business Unit: Specialty Reagents - Transglutaminase specialty reagents
Highlighted Profile Features:
Business Unit: Drug Discovery - Design of small molecule transglutaminase inhibitors
- TG2 Blockers for Celiac Disease: Pioneering advancements in therapeutic solutions for individuals with celiac disease.
- TG2 Blockers for Fibrotic Disorders: Spearheading research to combat fibrotic and inflammatory disorders using innovative TG2 blockers.
- FXIIIa (F13a) Blockers for Anticoagulation: Groundbreaking work in developing anticoagulants targeting FXIIIa, contributing to safe treatments.
Business Unit: Specialty Reagents - Transglutaminase specialty reagents
- Microbial Transglutaminase (Andracon™): Offering cutting-edge microbial transglutaminase for enzymatic Antibody Drug Conjugate (ADC) generation or tissue scaffold formation.
- Diagnostic Antigens: Providing essential diagnostic antigens crucial for medical testing and research.
- Transglutaminase R&D Products: 250 unique transglutaminase R&D products, shaping the future of biotech research.
Document
Discover Our New Catalogue Edition and Dive into the World of Transglutaminases! 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation